1) Strategic Leadership and Priorities - Baxter's turnaround strategy is gaining traction, with a focus on stabilizing the business, strengthening the balance sheet, and embedding continuous improvement through Baxter GPS. - John Rogers has joined as the new CFO, bringing experience in transformation and performance improvement. - The company is committed to creating long-term shareholder value and has raised its full-year outlook for organic sales growth and adjusted earnings per share.

2) Financial Performance and Segment Results - Q3 2026 global sales reached approximately $3 billion, reflecting a 5% increase both reported and organically. - Adjusted earnings were $0.58 per diluted share, a 16% decline YoY due to higher effective tax rates and the absence of prior year tax benefits. - Key segments: - Medical Products and Therapies (MPT) sales were $2.1 billion (+6% YoY), driven by Infusion Systems and Drug Compounding. - Advanced Surgery sales grew 12% to $342 million, supported by strong demand and commercial execution. - Healthcare Systems & Technologies (HST) sales totaled $806 million (+4% YoY), with Care & Connectivity Solutions contributing significantly.

3) Challenges and Headwinds - The company is addressing supply challenges related to a contract manufacturer and has decided to discontinue production of cephalosporin products, which is expected to impact 2026 sales by approximately $50 million. - The decision to discontinue cephalosporin production aims to simplify operations and improve supply resiliency, while also addressing FDA concerns. - Inflationary pressures and tariff impacts are anticipated to increase in 2027, which may affect margins and overall performance.

4) Operational and Product Plans - Baxter GPS is being integrated into operations, with over 700 continuous improvement initiatives completed year-to-date. - The company is focused on enhancing product quality and operational performance, particularly in the Advanced Surgery and Infusion Systems segments. - New product launches, such as Connex 360 and the Dynamo Series Smart Stretcher, are gaining traction and contributing to growth.

5) Guidance and Outlook - Baxter has raised its full-year organic sales growth outlook to 3%-4% from a previous range of 2%-3%. - Adjusted earnings per diluted share guidance has been increased to $2.05-$2.15, up from $1.95-$2.15. - The company will provide detailed guidance for 2027 in February, with expectations of continued challenges from inflation, tariffs, and product exits impacting margins.

Bottom line: Baxter is showing positive momentum in its turnaround efforts, with improved sales and earnings outlooks for 2026. However, challenges remain, particularly regarding supply chain issues and inflationary pressures, which could impact future performance. Shareholders should remain cautiously optimistic as the company continues to execute its strategic priorities.